medigraphic.com

2016, Number 4

<< Back Next >>

Rev Fac Med UNAM 2016; 59 (4)

Asthma in pediatrics

Navarrete-Rodríguez E, Sienra-Monge JJL, Pozo-Beltrán CF

Language: Spanish
References: 37
Page: 5-15
PDF size: 381.64 Kb.


ABSTRACT

Asthma is a chronic inflammatory disorder of the airways, which leads to recurrent episodes of wheezing, shortness of breath, chest tightness and/or cough; now is considered a public health problem in many countries, in Mexico the prevalence is estimated in 8%.
Asthma can be divided in two groups: allergic asthma, IgE-mediated and primarily triggered by airborne allergens and no allergic asthma whose etiological factors are infections, irritants, etc. The main components to be identified before starting treatment are: severity, control, response to drugs and disability. Medications to treat asthma can be classified as relievers, drugs used in acute situations or controllers, medications taken daily on a long-term basis to keep asthma under clinical control chiefly through their anti-inflammatory effects. The therapeutic decisions must be installed dynamic, moving from one to another stage, according to the symptoms. In case an allergen is the trigger of the symptoms, the recommended treatment is immunotherapy in order to reduce the allergic response especially in cases where the allergen can not be avoided.


REFERENCES

  1. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. Disponible en: http://www.ginasthma.org/.

  2. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and managment of asthma summary report 2007. J Allergy Clinimmunol. 2007 Nov; 120 (5 suppl): S94-138

  3. ISAAC Stering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The Lancet. 1998;351:1225-32.

  4. Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S; International Study of Asthma and Allergies in Childhood Phase Three Study Group. Global variation in the prevalence and severity of asthma symptoms: Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009 Jun;64(6):476-83

  5. Del-Rio-Navarro B, Del Rio-Chivardi JM, Berber A, Sienra- Monge JJ, Rosas-Vargas MA, Baeza-Bacab M. Asthma prevalence in children living in north Mexico City and a comparison with other Latin American cities and world regions. Allergy Asthma Proc. 2006 Jul-Aug;27(4):334-40.

  6. Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK; ISAAC Phase Three Study Group et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006 Aug 26;368(9537): 733-43.

  7. Shore SA. Obesity and asthma: possible mechanisms. J Allergy Clin Immunol. 2008 May;121(5):1087-93

  8. Larenas Linnemann D, Arias Cruz A, Guidos Fogelbach GA, Cid del Prado ML. Allergens used in skin tests in Mexico. Rev Alerg Mex. 2009 Mar-Apr;56(2):41-7.

  9. Bousquet J, Heinzerling L, Bachert C, Papadopoulos NG, Bousquet PJ, Burney PG, Global Allergy and Asthma European Network, et al; Allergic Rhinitis and its Impact on Asthma. Practical guide to skin prick tests in allergy to aeroallergens. Allergy. 2012 Jan;67(1):18-24

  10. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an im- portant risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000 May;161(5):1501-7.

  11. Dezateux C, Stocks J, Dundas I, Fletcher ME. Impaired airway function and wheezing in infancy: the influence of maternal smoking and a genetic predisposition to asthma. Am J Respir Crit Care Med. 1999 Feb;159(2):403-10.

  12. Uzzaman A, Cho SH. Chapter 28: Classification of hypersensitivity reactions. Allergy Asthma Proc. 2012 May- Jun;33 Suppl 1:S96-9.

  13. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2007. Available from: http://www.ginasthma.org/.

  14. Bisgaard H. Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature. Pediatr Pulmonol. 2000 Mar;29(3):221-34.

  15. Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med. 2004 May 18; 140(10):802-13.

  16. Walters EH, Walters J. Inhaled short acting beta2-agonist use in chronic asthma: regular versus as needed treatment. Cochrane Database Syst Rev. 2003;(2):CD001285.

  17. Rosas-Vargas M, del Rio-Chivardi J, Castro-Hidalgo E, del Rio-Navarro BE, Sienra-Monge JJL. Tipos y características de los inhaladores para el Manejo de asma. Bol Med Hosp Infant Mex. 2005Sep-Oct;113:11-7,

  18. Cates CJ, Crilly JA, Rowe BH. Cámaras espaciadoras versus nebulizadores para el tratamiento del asma aguda con betaagonistas (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, número 3, 2008. Oxford, Update Software Ltd. Disponible en: http://www.update-software. com. (Traducida de The Cochrane Library, Issue. Chichester, UK: John Wiley & Sons, Ltd.).

  19. Castillo Laita JA, De Benito Fernández J, Escribano Montaner A, Fernández Benítez M, García de la Rubia S, Garde Garde J, et al. Consensus statement on the management of paediatric asthma. Update 2007. First Spanish Consensus for the Management of Asthma in Paediatrics. Allergol Immunopathol (Madr). 2008 Jan-Feb;36(1):31-52.

  20. Iramain R, López-Herce J, Coronel J, et al. Inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. J Asthma. 2011 Apr;48(3):298-303.

  21. Plotnick LH, Ducharme FM. Combined inhaled anticholinergics and beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev. 2000;(4):CD000060.

  22. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008 Jan;31(1):143-78.

  23. Amirav I, Newhouse MT, Minocchieri S, Castro-Rodriguez JA, Schüepp KG. Factors that affect the efficacy of inhaled corticosteroids for infants and young children. J Allergy Clin Immunol. 2010 Jun;125(6):1206-11.

  24. Bacharier LB, Boner A, Carlsen KH, Eigenmann PA, Frischer T, Götz M; European Pediatric Asthma Group, et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy. 2008 Jan;63(1):5- 34.

  25. Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med. 2005 Feb;171(4):315-22.

  26. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med. 2011 May 5;364(18):1695-707.

  27. Anselmo M. Pediatric asthma controller therapy. Paediatr Drugs. 2011 Feb 1;13(1):11-7.

  28. Grupo de trabajo “Consenso Mexicano de Asma”. Guía Mexicana de asma. Neumología y cirugía de tórax. 2009;68: suplemento 2.

  29. Chapman KR, Barnes NC, Greening AP, Jones PW, Pedersen S. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax. 2010 Aug;65(8):747-52.

  30. Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD005307.

  31. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998 Oct;102(4 Pt 1):558-62.

  32. Calderón MA, Penagos M, Durham SR. Sublingual immunotherapy for allergic Rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases. Clin Allergy Immunol. 2008;21:359-75.

  33. Compalati E, Penagos M, Tarantini F, Passalacqua G, Canonica GW. Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunol. 2009 Jan;102(1):22-8.

  34. Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009 Dec; 124(6):1210-6.

  35. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab Clin Exp Allergy. 2009 Jun;39(6):788-97.

  36. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011 Jan;139(1):28-35.

  37. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of omalizumab (anti- IgE) for asthma in inner-city children. N Engl J Med. 2011 Mar 17;364(11):1005-15.




2020     |     www.medigraphic.com